cas 822-36-6|| where to buy 4-Methylimidazole

Nom du produit:4-Methylimidazole

IUPAC Name:5-methyl-1H-imidazole

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM330555-1000g	in stock	ǊƓ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 822-36-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:822-36-6; Formule moléculaire:C4H6N2; Point de fusion:-; Code SMILES:N1=CNC(=C1)C; Densité:

: Numéro de catalogue:CM330555; Poids moléculaire:82.11; Point d'ébullition:; N° Mdl:MFCD00005201; Stockage:2-8°C

: Imidazoles; Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.; Imidazole Manufacturer; As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

: PF-06648671; The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer’s Disease”. Amyloid β-peptide (Aβ) accumulation is one of the key hallmarks of Alzheimer’s disease (AD). γ-secretase cleaves the amyloid precursor protein (APP) into pathologically relevant Aβs, and has been widely studied as a potential target for the treatment of AD.
Pfizer‘s PF-06648671 is a Gamma secretase modulator (GSM) targeting APP processing. It is found to have excellent central exposure in human and robust reduction of amyloidogenic forms (Aβ42) in cerebrospinal fluid (CSF).